VKORC1 haplotypes in five East-Asian populations and Indians

Pharmacogenomics

Volumn 10, Issue 10, 2009, Pages 1609-1616

  Lee, Ming Ta Michael ^a,b   Chen, Chien Hsiun ^a   Chuang, Hui Ping ^a   Lu, Liang Suei ^a   Chou, Ching Heng ^a   Chen, Ying Ting ^a   Liu, Chih Yang ^a   Wen, Ming Shien ^c   Lu, Jang Jih ^d   Chang, Chi Feng ^e   Wu, Jer Yuarn ^a   Chen, Yuan Tsong ^a,f  

^a INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^d CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e Pharmigene Inc   (Taiwan)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Asian; Haplotype; SNP; VKORC1; Warfarin

Indexed keywords

ADENINE; CYTOSINE; GUANINE; OXIDOREDUCTASE; THYMINE; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE SUBUNIT 1; WARFARIN;

ARTICLE; ASIA; CHINESE; CONTROLLED STUDY; EAST ASIA; FILIPINO; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC VARIABILITY; GEOGRAPHIC DISTRIBUTION; HAPLOTYPE; HUMAN; INDIA; INDONESIA; NUCLEIC ACID BASE SUBSTITUTION; POPULATION DIFFERENTIATION; SINGLE NUCLEOTIDE POLYMORPHISM; THAILAND; VIET NAM;

ALLELES; ANTICOAGULANTS; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; CONTINENTAL POPULATION GROUPS; ETHNIC GROUPS; GENE FREQUENCY; GENETICS, POPULATION; HAPLOTYPES; HUMANS; INDIA; INDONESIA; LINKAGE DISEQUILIBRIUM; MIXED FUNCTION OXYGENASES; PHARMACOGENETICS; PHILIPPINES; POLYMORPHISM, SINGLE NUCLEOTIDE; THAILAND; VIETNAM; WARFARIN;

EID: 70649084118     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.09.80     Document Type: Article

References (19)

1. Hirsh J: Antithrombotic therapy in deep vein thrombosis and pulmonary embolism. Am. Heart J. 123, 1115-1122 (1992).
2. Hirsh J, Dalen J, Anderson DR et al.: Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 119, S8-S21 (2001). (Pubitemid 32154192)
3. Laupacis A, Albers G, Dalen J, Dunn M, Feinberg W, Jacobson A: Antithrombotic therapy in atrial fibrillation. Chest 108, S352-S359 (1995).
4. Stein PD, Alpert JS, Copeland J, Dalen JE, Goldman S, Turpie AG: Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest 108, S371-S379 (1995).
5. Rieder MJ, Reiner AP, Gage BF et al.: Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med. 352, 2285-2293 (2005). •• First paper to show VKORC1 haplotypes and their association with warfarin dose requirement.
6. Wadelius M, Chen LY, Eriksson N et al.: Association of warfarin dose with genes involved in its action and metabolism. Hum. Genet. 121, 23-34 (2007). (Pubitemid 46421137)
7. Yuan HY, Chen JJ, Lee MT et al.: A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum. Mol. Genet. 14, 1745-1751 (2005).
8. Wen MS, Lee M, Chen JJ et al.: Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes. Clin. Pharmacol. Ther. 84, 83-89 (2008). (Pubitemid 351861488)
9. Wu AH, Wang P, Smith A et al.: Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations. Pharmacogenomics 9, 169-178 (2008). (Pubitemid 351566941)
10. Gage BF, Eby C, Johnson JA et al.: Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin. Pharmacol. Ther. 84, 326-331 (2008).
11. Klein TE, Altman RB, Eriksson N et al.: Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med. 360, 753-764 (2009). •• Developed the first global dosing algorithm using a dataset from multiple populations.
12. Excoffier L, Slatkin M: Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol. Biol. Evol. 12, 921-927 (1995).
13. Takahashi H, Wilkinson GR, Nutescu EA et al.: Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet. Genomics 16, 101-110 (2006). • One of the first papers to show population differences in VKORC1 SNPs. (Pubitemid 43145678)
14. Lee SC, Ng SS, Oldenburg J et al.: Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population. Clin. Pharmacol. Ther. 79, 197-205 (2006). (Pubitemid 43297012)
15. Perini JA, Petzl-Erler ML, Tsuneto LT, Suarez-Kurtz G: VKORC1 polymorphisms in Amerindian populations of Brazil. Pharmacogenomics 9, 1623-1629 (2008). •• Demonstrated distributions of four VKORC1 SNPs in rare Amerindian populations of Brazil.
16. Perini JA, Struchiner CJ, Silva-Assuncao E et al.: Pharmacogenetics of warfarin: development of a dosing algorithm for Brazilian patients. Clin. Pharmacol. Ther. 84, 722-728 (2008).
17. Michaud V, Vanier MC, Brouillette D et al.: Combination of phenotype assessments and CYP2C9-VKORC1 polymorphisms in the determination of warfarin dose requirements in heavily medicated patients. Clin. Pharmacol. Ther. 83, 740-748 (2008). (Pubitemid 351556023)
18. Schelleman H, Chen Z, Kealey C et al.: Warfarin response and vitamin K epoxide reductase complex 1 in African Americans and Caucasians. Clin. Pharmacol. Ther. 81, 742-747 (2007). (Pubitemid 46625114)
19. Lal S, Sandanaraj E, Jada SR et al.: Influence of APOE genotypes and VKORC1 haplotypes on warfarin dose requirements in Asian patients. Br. J. Clin. Pharmacol. 65, 260-264 (2008). (Pubitemid 351171275)